Alfonso Marchianò

8.4k total citations · 2 hit papers
153 papers, 5.5k citations indexed

About

Alfonso Marchianò is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Surgery. According to data from OpenAlex, Alfonso Marchianò has authored 153 papers receiving a total of 5.5k indexed citations (citations by other indexed papers that have themselves been cited), including 83 papers in Pulmonary and Respiratory Medicine, 47 papers in Radiology, Nuclear Medicine and Imaging and 34 papers in Surgery. Recurrent topics in Alfonso Marchianò's work include Lung Cancer Diagnosis and Treatment (41 papers), Hepatocellular Carcinoma Treatment and Prognosis (27 papers) and Radiomics and Machine Learning in Medical Imaging (26 papers). Alfonso Marchianò is often cited by papers focused on Lung Cancer Diagnosis and Treatment (41 papers), Hepatocellular Carcinoma Treatment and Prognosis (27 papers) and Radiomics and Machine Learning in Medical Imaging (26 papers). Alfonso Marchianò collaborates with scholars based in Italy, United States and Germany. Alfonso Marchianò's co-authors include Ugo Pastorino, Nicola Sverzellati, Vincenzo Mazzaferro, Gabriella Sozzi, Carlo Spreafico, Carlo Morosi, Carlo La Vecchia, F Garbagnati, Mattia Boeri and Mario Silva and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Alfonso Marchianò

150 papers receiving 5.3k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: A phase 2 study

2012 363 citations Vincenzo Mazzaferro, Sherrie Bhoori et al. profile →
Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy

2019 359 citations Ugo Pastorino, Mario Silva et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alfonso Marchianò Italy	38	2.5k	1.7k	1.3k	1.0k	920	153	5.5k
Ravi Murthy United States	42	2.0k 0.8×	2.8k 1.7×	1.6k 1.2×	1.8k 1.8×	1.6k 1.7×	151	6.8k
Anne M. Covey United States	33	1.7k 0.6×	2.4k 1.4×	640 0.5×	1.6k 1.6×	897 1.0×	117	5.1k
Khaled M. Elsayes United States	35	1.2k 0.5×	1.5k 0.9×	1.2k 0.9×	892 0.9×	1.2k 1.3×	245	5.9k
Hideyuki Sakurai Japan	37	2.3k 0.9×	589 0.4×	937 0.7×	813 0.8×	546 0.6×	352	4.7k
Yasuaki Arai Japan	35	1.8k 0.7×	1.8k 1.1×	745 0.6×	972 1.0×	718 0.8×	244	4.5k
Marshall E. Hicks United States	45	2.4k 0.9×	1.9k 1.1×	607 0.5×	1.4k 1.4×	1.3k 1.4×	114	6.2k
Daniel Y. Sze United States	51	2.7k 1.1×	2.1k 1.3×	1.2k 0.9×	1.2k 1.2×	1.4k 1.5×	227	7.9k
Boris Guiu France	42	1.4k 0.6×	2.6k 1.6×	1.3k 0.9×	1.5k 1.5×	1.8k 2.0×	229	6.4k
Evan S. Siegelman United States	54	1.6k 0.6×	1.1k 0.7×	2.1k 1.6×	708 0.7×	1.3k 1.4×	173	8.7k
Anne Aupérin France	41	2.4k 0.9×	937 0.6×	863 0.6×	2.1k 2.1×	1.2k 1.3×	119	6.7k

Countries citing papers authored by Alfonso Marchianò

Since Specialization

Citations

This map shows the geographic impact of Alfonso Marchianò's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alfonso Marchianò with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alfonso Marchianò more than expected).

Fields of papers citing papers by Alfonso Marchianò

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alfonso Marchianò. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alfonso Marchianò. The network helps show where Alfonso Marchianò may publish in the future.

Co-authorship network of co-authors of Alfonso Marchianò

This figure shows the co-authorship network connecting the top 25 collaborators of Alfonso Marchianò. A scholar is included among the top collaborators of Alfonso Marchianò based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alfonso Marchianò. Alfonso Marchianò is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Calareso, Giuseppina, Chiara Marzi, Michela Baccini, et al.. (2024). Cylindrical TGR as early radiological predictor of RLT progression in GEPNETs: a proof of concept. Scientific Reports. 14(1). 15782–15782. 1 indexed citations

Boeri, Mattia, Federica Sabia, Roberta Eufrasia Ledda, et al.. (2024). Blood microRNA testing in participants with suspicious low-dose CT findings: follow-up of the BioMILD lung cancer screening trial. The Lancet Regional Health - Europe. 46. 101070–101070. 6 indexed citations

Milanese, Gianluca, Roberta Eufrasia Ledda, Federica Sabia, et al.. (2023). Ultra-low dose computed tomography protocols using spectral shaping for lung cancer screening: Comparison with low-dose for volumetric LungRADS classification. European Journal of Radiology. 161. 110760–110760. 10 indexed citations

Cosimo, Serena Di, Rosalba Miceli, Paolo Baili, et al.. (2022). Mammographic density to predict response to neoadjuvant systemic breast cancer therapy. Journal of Cancer Research and Clinical Oncology. 148(4). 775–781. 5 indexed citations

Pastorino, Ugo, Federica Sabia, Luigi Rolli, et al.. (2022). Cytisine Therapy Improved Smoking Cessation in the Randomized Screening and Multiple Intervention on Lung Epidemics Lung Cancer Screening Trial. Journal of Thoracic Oncology. 17(11). 1276–1286. 23 indexed citations

Maccauro, Marco, Carlo Spreafico, Gabriele Maffi, et al.. (2022). Radioembolization of Hepatocellular Carcinoma with 90Y Glass Microspheres: No Advantage of Voxel Dosimetry with Respect to Mean Dose in Dose–Response Analysis with Two Radiological Methods. Cancers. 14(4). 959–959. 10 indexed citations

Montomoli, Emanuele, Giovanni Apolone, Alessandro Manenti, et al.. (2021). Timeline of SARS-CoV-2 Spread in Italy: Results from an Independent Serological Retesting. Viruses. 14(1). 61–61. 9 indexed citations

Almond, Max, Fabio Tirotta, Hannah L. Tattersall, et al.. (2019). Diagnostic accuracy of percutaneous biopsy in retroperitoneal sarcoma. British journal of surgery. 106(4). 395–403. 31 indexed citations

Guidetti, Anna, Carmelo Carlo‐Stella, Silvia L. Locatelli, et al.. (2014). Phase II Study of Perifosine and Sorafenib Dual-Targeted Therapy in Patients with Relapsed or Refractory Lymphoproliferative Diseases. Clinical Cancer Research. 20(22). 5641–5651. 27 indexed citations

10.

Sozzi, Gabriella, Mattia Boeri, Marta Rossi, et al.. (2014). Clinical Utility of a Plasma-Based miRNA Signature Classifier Within Computed Tomography Lung Cancer Screening: A Correlative MILD Trial Study. Journal of Clinical Oncology. 32(8). 768–773. 318 indexed citations

11.

Guidetti, Anna, Carmelo Carlo‐Stella, Silvia L. Locatelli, et al.. (2012). Phase II study of sorafenib in patients with relapsed or refractory lymphoma. British Journal of Haematology. 158(1). 108–119. 38 indexed citations

12.

Sverzellati, Nicola, G. Randi, Elisa Calabrò, et al.. (2011). Interstitial lung diseases in a lung cancer screening trial. European Respiratory Journal. 38(2). 392–400. 128 indexed citations

13.

Ferrari, Andrea, Rosalba Miceli, Cristina Meazza, et al.. (2010). Comparison of the Prognostic Value of Assessing Tumor Diameter Versus Tumor Volume at Diagnosis or in Response to Initial Chemotherapy in Rhabdomyosarcoma. Journal of Clinical Oncology. 28(8). 1322–1328. 51 indexed citations

14.

Spreafico, Filippo, Lorenza Gandola, Paolo D’Angelo, et al.. (2010). Heterogeneity of Disease Classified as Stage III in Wilms Tumor: A Report From the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP). International Journal of Radiation Oncology*Biology*Physics. 82(1). 348–354. 18 indexed citations

15.

Calabrò, Elisa, G. Randi, Carlo La Vecchia, et al.. (2009). Lung function predicts lung cancer risk in smokers: a tool for targeting screening programmes. European Respiratory Journal. 35(1). 146–151. 64 indexed citations

16.

Luksch, Roberto, Marta Podda, Lorenza Gandola, et al.. (2005). Stage 4 neuroblastoma: sequential hemi-body irradiation or high-dose chemotherapy plus autologous haemopoietic stem cell transplantation to consolidate primary treatment. British Journal of Cancer. 92(11). 1984–1988. 10 indexed citations

17.

Damascelli, B, Gianluigi Patelli, Laura Frigerio, et al.. (1997). Placement of long-term central venous catheters in outpatients: study of 134 patients over 24,596 catheter days.. American Journal of Roentgenology. 168(5). 1235–1239. 50 indexed citations

18.

Damascelli, B, M. G. Bonalumi, Alfonso Marchianò, et al.. (1990). High technology long term central venous access: The radiological content. Journal of interventional radiology. 5(4). 153–161. 3 indexed citations

19.

Bedini, Annalida, Luca Tavecchio, M. G. Bonalumi, et al.. (1990). Reliability of prolonged infusion in cancer chemotherapy with the Groshong central venous catheter. 3(4). 232–234. 5 indexed citations

20.

Damascelli, B, et al.. (1987). Magnetic resonance imaging of extracranial neurogenic tumors. 1(1). 27–37. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact